Nasdaq News

The following are today's upgrades for Validea's Low PE Investor model based on the published strategy of John Neff. This strategy looks for firms with persistent earnings growth that trade at a discount relative to their earnings growth and dividend yield.

The following are today's upgrades for Validea's Book/Market Investor model based on the published strategy of Joseph Piotroski. This value-quant strategy screens for high book-to-market stocks, and then separates out financially sound firms by looking at a host of improving f

The following are today's upgrades for Validea's Price/Sales Investor model based on the published strategy of Kenneth Fisher. This value strategy rewards stocks with low P/S ratios, long-term profit growth, strong free cash flow and consistent profit margins.

The following are today's upgrades for Validea's P/E/Growth Investor model based on the published strategy of Peter Lynch. This strategy looks for stocks trading at a reasonable price relative to earnings growth that also possess strong balance sheets.

The tennis governing bodies have joined forces to support lower-level professionals who are struggling financially during the sport's shutdown due to the novel coronavirus outbreak.

Investors in Iovance Biotherapeutics Inc (Symbol: IOVA) saw new options become available today, for the July 17th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 91 days until expiration the newly availa

A final-hour rally helped each of the major indices finish Thursday’s session on positive ground, despite another week of alarmingly high jobless claims. But the NASDAQ really didn’t need any late-day heroics. The index continued to easily outperform its counterparts than

A 9.8% contraction of the Chinese economy in Q1 did not derail investor optimism today, which saw Asia Pacific stocks rally strongly after Gilead reported very preliminary positive testing of its drug to fight the coronavirus

Stocks most affected by the viral outbreak are soaring, while those that have been havens for investors are down Friday morning. Trump’s plans for reopening the economy lifting the market, too.

The markets today are in a giddy mood thanks to preliminary data from a Gilead Sciences (GILD) study using the antiviral treatment remdesivir on COVID-19 patients that found the drug highly effective.

As if the coronavirus pandemic itself isn't bad enough, there are lots of scammers out there taking advantage of it -- at our expense. Many websites, including government ones like the Federal Trade Commission (FTC), the Internal Revenue Service (IRS), and the Consumer Financial

(RTTNews) - Kansas City Southern (KSU) revealed earnings for its first quarter that increased from last year.

Clinical trial service providers report a spike in demand for virtual trials as pharmaceutical companies try to prevent the coronavirus outbreak from derailing their drug rollouts.

(RTTNews) - French stocks rose sharply on Friday after U.S. President Donald Trump announced new guidelines to states aimed at easing social distancing restrictions and reopening parts of the country.

The start of the MotoGP season has been pushed back further into the European summer after German Grand Prix organisers sought a postponement due to extended restrictions on major events as a result of the COVID-19 pandemic.

Merging money-losing state carrier Malaysia Airlines Bhd (MAB) with budget airline AirAsia Group Bhd is one of the options to "save" them as the COVID-19 crisis batters the industry, Malaysia's second-most senior minister told Reuters on Friday.

Britain's stock markets jumped on Friday as investors cheered plans for a gradual restarting of the U.S. economy and encouraging data on possible treatment for the COVID-19 disease.

Cricket South Africa (CSA) confirmed on Friday they had made former test skipper Graeme Smith's tenure as director of cricket permanent, keeping him in the role until March 2022.

(RTTNews) - German stocks rallied on Friday as investors overlooked bleak China growth data and cheered reports suggesting that the experimental Covid-19 treatment remdesivir is showing promise in a Chicago clinical trial.

London-based Brewin Dolphin saw 7.1 billion pounds wiped off the funds it manages in its last quarter and said on Friday it could not predict the effect of the coronavirus pandemic on profitability as the worst selloff in a decade hammered investments.